rectum adenocarcinoma
rectum cancer that derives from epithelial cells of glandular origin
Press Enter · cited answer in seconds
0 sources
rectum adenocarcinoma
Summary
rectum adenocarcinoma is a class of disease[1].
Key Facts
- rectum adenocarcinoma's instance of is recorded as class of disease[2].
- rectum adenocarcinoma's subclass of is recorded as rectum cancer[3].
- rectum adenocarcinoma's subclass of is recorded as adenocarcinoma[4].
- rectum adenocarcinoma's Commons category is recorded as Adenocarcinomas of the human rectum[5].
- rectum adenocarcinoma's Disease Ontology ID is recorded as DOID:1996[6].
- rectum adenocarcinoma's anatomical location is recorded as rectum[7].
- rectum adenocarcinoma's NCI Thesaurus ID is recorded as C9383[8].
- rectum adenocarcinoma's drug or therapy used for treatment is recorded as bevacizumab[9].
- rectum adenocarcinoma's drug or therapy used for treatment is recorded as cetuximab[10].
- rectum adenocarcinoma's drug or therapy used for treatment is recorded as capecitabine[11].
- rectum adenocarcinoma's drug or therapy used for treatment is recorded as irinotecan[12].
- rectum adenocarcinoma's drug or therapy used for treatment is recorded as oxaliplatin[13].
- rectum adenocarcinoma's drug or therapy used for treatment is recorded as regorafenib[14].
- rectum adenocarcinoma's drug or therapy used for treatment is recorded as fluorouracil[15].
- rectum adenocarcinoma's exact match is recorded as http://purl.obolibrary.org/obo/DOID_1996[16].
- rectum adenocarcinoma's exact match is recorded as http://identifiers.org/doid/DOID:1996[17].
- rectum adenocarcinoma's UMLS CUI is recorded as C0149978[18].
- rectum adenocarcinoma's on focus list of Wikimedia project is recorded as WikiProject Medicine[19].
- rectum adenocarcinoma's Mondo ID is recorded as MONDO_0002169[20].
- rectum adenocarcinoma's ICD-11 ID is recorded as 2B92.0[21].
- rectum adenocarcinoma's ICD-11 ID is recorded as 1316028436[22].
- rectum adenocarcinoma's Experimental Factor Ontology ID is recorded as 0005631[23].